Assembly Biosciences (ASMB) financial statements
Assembly Biosciences reported revenue of $72M in fiscal 2025, up 29.7% a year over 8 years.
Net income was -$6M.
Free cash flow was -$41M.
The diluted share count fell 35% over the period (buybacks).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Assembly Biosciences's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $9M | $15M | $16M | $79M | $6M | $0 | $7M | $29M | $72M |
| Research and development | $33M | $44M | $73M | $86M | $107M | $69M | $70M | $49M | $56M | $65M |
| Selling, general and admin | $12M | $17M | $35M | $33M | $37M | $29M | $24M | $23M | $18M | $20M |
| Operating income | -$45M | -$52M | -$93M | -$103M | -$65M | -$133M | -$94M | -$65M | -$45M | -$12M |
| Pre-tax income | -$45M | -$52M | -$90M | -$98M | -$62M | -$132M | -$93M | -$61M | -$40M | -$6M |
| Income tax | -$618,000 | -$9M | $1M | -$774,000 | $0 | -$3M | $0 | $33,000 | $330,000 | $0 |
| Net income | -$44M | -$43M | -$91M | -$98M | -$62M | -$130M | -$93M | -$61M | -$40M | -$6M |
| EPS (diluted) | -$2.57 | -$2.41 | -$3.98 | -$3.72 | -$1.75 | -$3.00 | -$23.08 | -$13.38 | -$6.69 | -$0.55 |
| Diluted shares | 17M | 18M | 23M | 26M | 35M | 43M | 4M | 5M | 6M | 11M |
| Operating margin | — | -579.1% | -626.4% | -643.4% | -81.9% | -2121.7% | — | -902.5% | -159.3% | -16.8% |
| Net margin | — | -474.7% | -613.0% | -611.6% | -78.6% | -2076.4% | — | -854.8% | -140.9% | -8.5% |
Balance sheet
Fiscal years, from Assembly Biosciences's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $53M | $120M | $218M | $274M | $216M | $147M | $92M | $130M | $112M | $248M |
| Receivables | $0 | $2M | $2M | $3M | $1M | $336,000 | $944,000 | $43,000 | $0 | $974,000 |
| Total current assets | $54M | $123M | $223M | $283M | $224M | $154M | $97M | $134M | $116M | $255M |
| Property, plant and equipment | $214,687 | $860,000 | $557,000 | $2M | $2M | $1M | $743,000 | $385,000 | $284,000 | $221,000 |
| Goodwill | $13M | $13M | $13M | $13M | $13M | — | — | — | — | — |
| Total assets | $98M | $169M | $268M | $340M | $283M | $191M | $102M | $137M | $119M | $258M |
| Total current liabilities | $7M | $13M | $18M | $24M | $24M | $16M | $16M | $39M | $48M | $49M |
| Total liabilities | $18M | $56M | $57M | $67M | $43M | $22M | $19M | $96M | $86M | $51M |
| Shareholders' equity | $80M | $113M | $211M | $273M | $241M | $169M | $83M | $41M | $33M | $207M |
| Net debt | -$29M | -$82M | -$41M | -$47M | -$59M | -$46M | -$52M | -$20M | -$38M | -$58M |
Cash flow
Fiscal years, from Assembly Biosciences's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$35M | $2M | -$65M | -$84M | -$63M | -$93M | -$84M | $23M | -$51M | -$41M |
| Capital spending | $147,000 | $865,000 | $340,000 | $2M | $470,000 | $3M | $102,000 | $255,000 | $28,000 | $66,000 |
| Free cash flow | -$35M | $995,000 | -$65M | -$86M | -$63M | -$96M | -$85M | $22M | -$51M | -$41M |
| Stock-based compensation | $5M | $9M | $28M | $21M | $22M | $5M | $7M | $5M | $3M | $5M |
| Free cash flow margin | — | 11.0% | -441.1% | -536.4% | -80.2% | -1542.9% | — | 313.9% | -179.3% | -56.9% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ASMB.
Open ASMB in InvestinglyQuestions
What was Assembly Biosciences's revenue in 2025?
$72M in fiscal 2025, from its 10-K filing.
How much free cash flow does Assembly Biosciences generate?
-$41M in fiscal 2025 (operating cash flow minus capital spending).
From Assembly Biosciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.